CryoPort (NASDAQ:CYRX) CEO Jerrell Shelton Sells 2,894 Shares of Stock

CryoPort, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 2,894 shares of the firm’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $8.18, for a total value of $23,672.92. Following the completion of the sale, the chief executive officer owned 1,051,607 shares of the company’s stock, valued at approximately $8,602,145.26. This represents a 0.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jerrell Shelton also recently made the following trade(s):

• On Monday, March 16th, Jerrell Shelton sold 7,918 shares of CryoPort stock. The shares were sold at an average price of $8.00, for a total transaction of $63,344.00.

CryoPort Price Performance

Shares of CryoPort stock traded up $0.26 during trading on Wednesday, hitting $8.41. The stock had a trading volume of 325,336 shares, compared to its average volume of 480,669. CryoPort, Inc. has a 12 month low of $4.63 and a 12 month high of $11.45. The firm’s fifty day simple moving average is $8.90 and its 200-day simple moving average is $9.32. The stock has a market cap of $419.32 million, a PE ratio of 6.37 and a beta of 1.69.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The firm had revenue of $45.45 million for the quarter, compared to the consensus estimate of $42.92 million. CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. Analysts expect that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CryoPort

Hedge funds have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. grew its stake in CryoPort by 37.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock worth $14,208,000 after purchasing an additional 408,263 shares in the last quarter. SG Americas Securities LLC raised its position in CryoPort by 663.2% during the 3rd quarter. SG Americas Securities LLC now owns 127,280 shares of the company’s stock valued at $1,207,000 after purchasing an additional 110,602 shares in the last quarter. Bullseye Asset Management LLC raised its position in CryoPort by 23.0% during the 2nd quarter. Bullseye Asset Management LLC now owns 260,168 shares of the company’s stock valued at $1,941,000 after purchasing an additional 48,605 shares in the last quarter. Thematics Asset Management lifted its holdings in shares of CryoPort by 12.8% in the 2nd quarter. Thematics Asset Management now owns 1,914,885 shares of the company’s stock worth $14,285,000 after buying an additional 216,937 shares during the period. Finally, Mak Capital One LLC purchased a new stake in shares of CryoPort in the 3rd quarter worth $7,756,000. 92.90% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CYRX has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of CryoPort in a research note on Monday, December 29th. Wall Street Zen downgraded CryoPort from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Needham & Company LLC increased their target price on CryoPort from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.94.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.